Laura Sherlock

Laura Sherlock

Auto-generated profile, based on publicly available information

Laura Sherlock

Centre for Clinical Brain Sciences, University of Edinburgh

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2024 in Cerebral Circulation - Cognition and Behavior
Verified
Journal Article
Open access
LSLaura Sherlock
Laura Sherlock
SLShun Fu Lee
Shun Fu Lee
TCTali Cukierman-Yaffe
Tali Cukierman-Yaffe
DLDarryl Leong
Darryl Leong
HGHertzel C. Gerstein
Hertzel C. Gerstein
WWWilliam N. Whiteley
William N. Whiteley
Background: Visit-to-visit variability in single biological measurements has been associated with cognitive decline and an elevated risk of cardiovascular diseases (CVD). However, the effect of visit-to-visit variability in multiple biological measures is underexplored. We investigated the effect of visit-to-visit variability in blood pressure (BP), heart rate (HR), weight, fasting plasma glucose, cholesterol, and triglycerides on cognitive performance and CVD. Methods: Data on BP, HR, weight, glucose, cholesterol, and triglycerides from study visits in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial were used to estimate the association between visit-to-visit variability, cognitive performance (Mini Mental State Examination (MMSE) score) and CVD (non-fatal stroke, non-fatal myocardial infarction, or cardiovascular death). Visit-to-visit variation for each measurement was estimated by calculating each individuals visit-to-visit standard deviation for that measurement. Participants whose standard deviation was in the highest quarter were classified as having high variation. Participants were grouped into those having 0, 1, 2, 3, or ≥ 4 high variation measurements. Regression and survival models were used to estimate the association between biological measures with MMSE and CVD with adjustment for confounders and mean measurement value. Results: After adjustment for covariates, higher visit-to-visit variability in BP, HR, weight, and FPG were associated with poorer MMSE and a higher risk of CVD. Effect sizes did not vary greatly by measurement. The effects of high visit-to-visit variability were additive; compared to participants who had no measurements with high visit-to-visit variability, those who had high visit-to-visit variability in ≥4 measurements had poorer MMSE scores (-0.63 (95 % CI -0.96 to -0·31). Participants with ≥4 measurements with high visit-to-visit variability compared to participants with none had higher risk of CVD (hazard ratio 2.46 (95 % CI 1.63 to 3.70). Conclusion: Visit-to-visit variability in several measurements were associated with cumulatively poorer cognitive performance and a greater risk of CVD.

13 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MIMatthew H Iveson
Matthew H Iveson
MMMome Mukherjee
Mome Mukherjee
EDEmma M Davidson
Emma M Davidson
HZHuayu Zhang
Huayu Zhang
LSLaura Sherlock
Laura Sherlock
WWWilliam N Whiteley
William N Whiteley
Importance Understanding the relevance of covert cerebrovascular disease (CCD) for later health will allow clinicians to more effectively monitor and target interventions. Objective To examine the association between clinically reported CCD, measured using natural language processing (NLP), and subsequent disease risk. Design, Setting and Participants We conducted a retrospective e-cohort study using linked health record data. From all people with clinical brain imaging in Scotland from 2010 to 2018, we selected people with no prior hospitalisation for neurological disease. The data were analysed from March 2024 to June 2025. Exposure Four phenotypes were identified with NLP of imaging reports: white matter hypoattenuation or hyperintensities (WMH), lacunes, cortical infarcts and cerebral atrophy. Main outcomes and measures Hazard ratios (aHR) for stroke, dementia, and Parkinson’s disease (conditions previously associated with CCD), epilepsy (a brain-based control condition) and colorectal cancer (a non-brain control condition), adjusted for age, sex, deprivation, region, scan modality, and pre-scan healthcare, were calculated for each phenotype. Results From 395,273 people with brain imaging and no history of neurological disease, 145,978 (37%) had ≥1 phenotype. For each phenotype, the aHR of any stroke was: WMH 1.4 (95%CI: 1.3–1.4), lacunes 1.6 (1.5–1.6), cortical infarct 1.7 (1.6–1.8), and cerebral atrophy 1.1 (1.0–1.1). The aHR of any dementia was: WMH, 1.3 (1.3–1.3), lacunes, 1.0 (0.9–1.0), cortical infarct 1.1 (1.0–1.1) and cerebral atrophy 1.7 (1.7–1.7). The aHR of Parkinson’s disease was, in people with a report of: WMH 1.1 (1.0–1.2), lacunes 1.1 (0.9–1.2), cortical infarct 0.7 (0.6–0.9) and cerebral atrophy 1.4 (1.3–1.5). The aHRs between CCD phenotypes and epilepsy and colorectal cancer overlapped the null. Conclusions and Relevance NLP identified CCD and atrophy phenotypes from routine clinical image reports, and these had important associations with future stroke, dementia and Parkinson’s disease. Prevention of neurological disease in people with CCD should be a priority for healthcare providers and policymakers. Question Are measures of Covert Cerebrovascular Disease (CCD) associated with the risk of subsequent disease (stroke, dementia, Parkinson’s disease, epilepsy, and colorectal cancer)? Findings This study used a validated NLP algorithm to identify CCD (white matter hypoattenuation/hyperintensities, lacunes, cortical infarcts) and cerebral atrophy from both MRI and computed tomography (CT) imaging reports generated during routine healthcare in >395K people in Scotland. In adjusted models, we demonstrate higher risk of dementia (particularly Alzheimer’s disease) in people with atrophy, and higher risk of stroke in people with cortical infarcts. However, associations with an age-associated control outcome (colorectal cancer) were neutral, supporting a causal relationship. It also highlights differential associations between cerebral atrophy and dementia and cortical infarcts and stroke risk. Meaning CCD or atrophy on brain imaging reports in routine clinical practice is associated with a higher risk of stroke or dementia. Evidence is needed to support treatment strategies to reduce this risk. NLP can identify these important, otherwise uncoded, disease phenotypes, allowing research at scale into imaging-based biomarkers of dementia and stroke.